Linked Life Data

10544508

Source:http://linkedlifedata.com/resource/pubmed/id/10544508

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10544508rdf:typepubmed:Citationlld:pubmed
pubmed-article:10544508lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0018939lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0229601lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0205282lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0882849lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C2004454lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0237753lld:lifeskim
pubmed-article:10544508lifeskim:mentionsumls-concept:C0035363lld:lifeskim
pubmed-article:10544508pubmed:issue4lld:pubmed
pubmed-article:10544508pubmed:dateCreated1999-11-16lld:pubmed
pubmed-article:10544508pubmed:abstractTextEngraftment in relation to infused CD34+ cell number was retrospectively analysed in 66 patients with hematological diseases: non-Hodgkin's lymphoma (n = 33), multiple myeloma (n = 21), acute myelogenous leukemia (n = 7), Hodgkin's disease (n = 4) and myelodysplastic syndrome (n = 1). Progenitor cells were mobilized with rhG-CSF, alone or in association with chemotherapy. The cells were harvested by leukapheresis until at least 2 x 10(6) CD34+/kg body weight were obtained. A total of 194 leukaphereses were performed (median = 3 per patient, range 1-9). A median of 3.40 x 10(8) nucleated cells/kg (range 0.31-27.59) and a median of 7.15 x 10(6) CD34+ cell/kg (range 1.31-115.70) were transplanted. Regardless of transfusional support or patient diagnosis, engraftment was rapid in patients who had received > or = 5 x 10(6) CD34+ cell/kg. In this case, absolute neutrophil blood count > or = 0.5 x 10(9)/l was obtained on day 12 post graft (range 7-19) and platelet count > or = 20 x 10(9)/l was also reached after the same median time interval (range 8-121). From the present results, a minimal threshold of 5 x 10(6) CD34+ cell/kg appears to be suitable for providing rapid and complete hematopoieitc reconstitution in patients exposed to high doses of chemotherapy with or without total body irradiation. Furthermore, administration of rhG-CSF during post-graft period significantly decreased the neutrophil time recovery (P = 0.002) but not that of platelets (P > 0.05).lld:pubmed
pubmed-article:10544508pubmed:languagefrelld:pubmed
pubmed-article:10544508pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10544508pubmed:citationSubsetIMlld:pubmed
pubmed-article:10544508pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10544508pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10544508pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10544508pubmed:statusMEDLINElld:pubmed
pubmed-article:10544508pubmed:monthAuglld:pubmed
pubmed-article:10544508pubmed:issn0001-5512lld:pubmed
pubmed-article:10544508pubmed:authorpubmed-author:NguyenB TBTlld:pubmed
pubmed-article:10544508pubmed:authorpubmed-author:FerrantAAlld:pubmed
pubmed-article:10544508pubmed:authorpubmed-author:De BruyèreMMlld:pubmed
pubmed-article:10544508pubmed:authorpubmed-author:StraetmansNNlld:pubmed
pubmed-article:10544508pubmed:authorpubmed-author:BoulasselM...lld:pubmed
pubmed-article:10544508pubmed:issnTypePrintlld:pubmed
pubmed-article:10544508pubmed:volume54lld:pubmed
pubmed-article:10544508pubmed:ownerNLMlld:pubmed
pubmed-article:10544508pubmed:authorsCompleteYlld:pubmed
pubmed-article:10544508pubmed:pagination191-6lld:pubmed
pubmed-article:10544508pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:meshHeadingpubmed-meshheading:10544508...lld:pubmed
pubmed-article:10544508pubmed:year1999lld:pubmed
pubmed-article:10544508pubmed:articleTitle[Hematopoietic recovery as a function of the number of autografted CD34+ cells: a retrospective study of 66 patients with malignant hematologic diseases].lld:pubmed
pubmed-article:10544508pubmed:affiliationLaboratoire d'immunohématologie, Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Bruxelles, Belgique. Rachid.boulassel@mblg.ucl.ac.belld:pubmed
pubmed-article:10544508pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10544508pubmed:publicationTypeEnglish Abstractlld:pubmed